Amgen Announces Results From Phase III PAVES Study Evaluating Neulasta

Amgen announced results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase III trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.
PR Newswire